Orencia Bristol-Myers Squibb Company - Treatment for Rheumatoid Arthritis
Orencia is a selective costimulation modulator, which inhibits T cell (T lymphocyte) activation. Orencia is indicated for the treatment of rheumatoid arthritis (RA).Posted: December 2005
Related articles
- U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD) - December 15, 2021
- Bristol-Myers Squibb’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults - July 6, 2017
- U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis - July 31, 2011
- Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on Orencia (Abatacept), an Investigational Selective Modulator of T-Cell Co-Stimulation for Rheumatoid Arthritis - September 6, 2005
- Bristol-Myers Squibb Provides Regulatory Update for Abatacept - December 23, 2004
Orencia (abatacept) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
